The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism

Paweena Susantitaphong, Somratai Vadcharavivad, Teerada Susomboon, Wanchana Singhan, Netsiri Dumrongpisutikul, Ketsuda Jakchairoongruang, Somchai Eiam-Ong, Kearkiat Praditpornsilpa, Paweena Susantitaphong, Somratai Vadcharavivad, Teerada Susomboon, Wanchana Singhan, Netsiri Dumrongpisutikul, Ketsuda Jakchairoongruang, Somchai Eiam-Ong, Kearkiat Praditpornsilpa

Abstract

Background: Secondary hyperparathyroidism (SHPT) is associated with high incidences of cardiovascular disease, bone fracture, and mortality. This study was conducted to demonstrate the effectiveness of cinacalcet treatment on chronic kidney disease-mineral bone disorder (CKD-MBD) markers in chronic hemodialysis patients with severe SHPT.

Methods: In phase 1, 30 adult HD patients were randomized to cinacalcet or control groups for 12 weeks to explore the achievement of >30% reduction of iPTH. In phase 2, 45 patients were participated to further explore the effect of cinacalcet on CKD-MBD parameters for 24-week follow up and 12 additional weeks after cinacalcet discontinuation.

Results: In phase 1, the baseline serum iPTH levels were not different [1374 (955, 1639) pg/mL in the control group vs. 1191 (1005, 1884) pg/mL in the cinacalcet group], the percentage of patients achieving iPTH target were significantly higher in the treatment group [80% vs. 13%, p = .001]. In phase 2, the significant reductions of iPTH, FGF-23, tartrate-resistant acid phosphatase 5b, and slightly decreased size of parathyroid gland and stabilized vascular calcification were observed at 24-week follow up and markedly rebounded after discontinuation of cinacalcet.

Conclusions: The effectiveness of cinacalcet were still obviously demonstrated even in chronic HD patients with severe SHPT. In addition, the improvements of bone markers and FGF-23, and stabilization of vascular calcification were observed. Therefore, cinacalcet can provide salutary effects on CKD-MBD in severe SHPT and might be an initially effective PTH-lowering therapy prior to surgical parathyroidectomy as well as an alternative treatment in the patients unsuitable for surgery.

Clinical trial registration: ClinicalTrials.gov: NCT02056730. Date of registration: February 4, 2014.

Keywords: Cinacalcet; chronic hemodialysis; severe secondary hyperparathyroidism.

Figures

Figure 1.
Figure 1.
The change of serum calcium, serum phosphate, oral medication calcium supplement and dialysate calcium following baseline, 3 weeks, 6 weeks. 9 weeks, and 12 weeks in cinacalcet and control groups in Phase 1. *p < .05 when compared with control group.
Figure 2.
Figure 2.
The change of serum iPTH following baseline, 3 weeks, 6 weeks, 9 weeks, and 12 weeks in cinacalcet and control groups in Phase 1. *p< .05 when compared with control group.

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group KDIGO clinical practice guideline for the diagnosis. Evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). Kidney Int. 2009;76:S1–S130.
    1. Leifheit-Nestler M, Große Siemer R, Flasbart K, et al. . Induction of cardiac FGF-23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:1088–1099.
    1. Bouma-de Krijger A, Bots ML, Vervloet MG, et al. . Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant. 2014;29:88–97.
    1. Cernaro V, Santoro D, Lucisano S, et al. . The future of phosphate binders: a perspective on novel therapeutics. Expert Opin Investig Drugs. 2014;23:1459–1463.
    1. Djukanović L, Dimković N, Marinković J, et al. . Association between hemodialysis patient outcomes and compliance with KDOQI and KDIGO targets for mineral and bone metabolism. Nephron. 2016;132:168–174.
    1. Ketteler M, Block GA, Evenepoel P, et al. . Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med. 2018;168:422–430.
    1. Fukagawa M, Yokoyama K, Koiwa F, et al. . Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247–288.
    1. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201.
    1. Moe SM, Chertow GM, Coburn JW, et al. . Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760–771.
    1. Messa P, Macário F, Yaqoob M, et al. . The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36–45.
    1. Palmer SC, Nistor I, Craig JC, et al. . Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10:e1001436.
    1. Zhang Q, Li M, You L, et al. . Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS One. 2012;7:e48070.
    1. Greeviroj P, Kitrungphaiboon T, Katavetin P, et al. . Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: a meta-analysis of randomized controlled trials. Nephron 2018;139:197–210.
    1. Sterrett JR, Strom J, Stummvoll HK, et al. . Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2007;68:10–17.
    1. Lindberg JS, Culleton B, Wong G, et al. . Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800–807.
    1. Moe SM, Drueke T, Lameire N, et al. . Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14:3–12.
    1. Martin KJ, Olgaard K, Coburn JW, et al. . Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43:558–565.
    1. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest. 2006;36:51–62.
    1. Rodriguez M Canalejo A, Garfia B, et al. . Pathogenesis of refractory hyperparathyroidism. Kidney Int. 2002;61:155–160.
    1. Indridason OS, Heath H, Khosla S, et al. . Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int. 1996;50:1663–1671.
    1. Fukuda N, Tanaka H, Fukagawa M, et al. . Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436–1413.
    1. Gogusev J, Duchambon P, Hory B, et al. . Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328–336.
    1. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288:F253–F264.
    1. Taniguchi M, Tokumoto M, Matsuo D, et al. . Persistent hyperparathyroidism in renal allograft recipients: Vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70:363.
    1. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int. 2006;70(Suppl 102):S3–S7.
    1. Tominaga Y, Numano M, Tanaka Y, et al. . Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:87–96.
    1. McCarron DA, Muther RS, Lenfesty B, et al. . Parathyroid function in persistent hyperparathyroidism: relationship to gland size. Kidney Int. 1982;22:662–670.
    1. Reams BD, Dluzniewski PJ, Do TP, et al. . Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design. BMC Nephrol. 2015;16:175.
    1. Komaba H, Nakanishi S, Fujimori A, et al. . Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5:2305–2314.
    1. Yamada S, Tokumoto M, Taniguchi M, et al. . Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism. Ther Apher Dial. 2015;19:367–377.
    1. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008;24:982–989.
    1. Faul C, Amaral AP, Oskouei B, et al. . FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408.
    1. Ureña-Torres PA, Floege J, Hawley CM, et al. . Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant. 2013;28:146–152.
    1. Lorenz K, Bartsch DK, Sancho JJ, et al. . Surgical management of secondary hyperparathyroidism in chronic kidney disease-a consensus report of the European Society of Endocrine Surgeons. Langenbecks Arch Surg. 2015;400:907–927.
    1. Liao SC, Moi SH, Chou FF, et al. . Changes in serum concentrations of fibroblast growth factor 23 and soluble klotho in hemodialysis patients after total parathyroidectomy. Biomed Res Int. 2016;2016:1.
    1. Takahashi H, Komaba H, Takahashi Y, et al. . Impact of parathyroidectomy on serum FGF-23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab.2014; 99:E652–E658.
    1. Apetrii M, Goldsmith D, Nistor I, et al. . Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) – a systematic review and meta-analysis. PLoS One. 2017;12:e0187025.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner